Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67


Meta-analysis reveals a lack of association between UGT2B17 deletion polymorphism and tumor susceptibility.

Deng X, Cheng Y, Yang X, Li S, Zhao R, Liu K, Liu J, Cao Q, Qin C, Shao P, Meng X, Li J, Lu Q, Yin C.

PLoS One. 2014 May 6;9(5):e96812. doi: 10.1371/journal.pone.0096812. eCollection 2014.


Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.

Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH, Dossett N, Lang N, Kadlubar FF, Ambrosone CB, Zachariah B, Heysek RV, Patterson S, Pow-Sang J.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1473-8.


Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.

Cai L, Huang W, Chou KC.

Protein Pept Lett. 2012 Jan;19(1):62-9.


The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians.

Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P.

Cancer Detect Prev. 2007;31(4):310-5.


Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.

Ishimaru S, Yuza Y, Kaneko T, Urashima M.

Pediatr Int. 2017 Apr;59(4):427-431. doi: 10.1111/ped.13198. Epub 2017 Jan 5.


The UGT2B17 gene deletion is not associated with prostate cancer risk.

Olsson M, Lindström S, Häggkvist B, Adami HO, Bälter K, Stattin P, Ask B, Rane A, Ekström L, Grönberg H.

Prostate. 2008 Apr 1;68(5):571-5. doi: 10.1002/pros.20700.


Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.

Lazarus P, Zheng Y, Runkle EA, Muscat JE, Wiener D.

Pharmacogenet Genomics. 2005 Nov;15(11):769-78.


Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.

Karypidis AH, Olsson M, Andersson SO, Rane A, Ekström L.

Pharmacogenomics J. 2008 Apr;8(2):147-51. Epub 2007 Mar 27.


The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.

Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, Chase GA, Richie J, Lazarus P.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):823-8.


Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.

Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF.

Pharmacogenet Genomics. 2015 May;25(5):263-9. doi: 10.1097/FPC.0000000000000135.


The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.

Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, Lesko SM, Muscat JE, Lazarus P, Gallagher CJ.

Cancer. 2013 Jul 1;119(13):2477-85. doi: 10.1002/cncr.28009. Epub 2013 Apr 10.


Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.

Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R, Pow-Sang J.

Urology. 2007 Aug;70(2):374-9.


Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios.

Anielski P, Simmchen J, Wassill L, Ganghofner D, Thieme D.

Drug Test Anal. 2011 Oct;3(10):645-51. doi: 10.1002/dta.332. Epub 2011 Sep 19.


Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.

Ménard V, Eap O, Harvey M, Guillemette C, Lévesque E.

Hum Mutat. 2009 Sep;30(9):1310-9. doi: 10.1002/humu.21054.


Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids.

Deshmukh N, Petróczi A, Barker J, Székely AD, Hussain I, Naughton DP.

Subst Abuse Treat Prev Policy. 2010 Apr 29;5:7. doi: 10.1186/1747-597X-5-7.


Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.

Chen G, Giambrone NE, Lazarus P.

Pharmacogenet Genomics. 2012 Mar;22(3):183-90. doi: 10.1097/FPC.0b013e32834ff3a5.


The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.

Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, Bélanger A, Labrie F, Ohlsson C.

J Clin Endocrinol Metab. 2007 Dec;92(12):4878-82. Epub 2007 Aug 14.


Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.

Mafune A, Hama T, Suda T, Suzuki Y, Ikegami M, Sakanashi C, Imai S, Nakashima A, Yokoo T, Wada K, Kojima H, Urashima M.

BMC Cancer. 2015 Mar 31;15:205. doi: 10.1186/s12885-015-1220-2.


UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse.

Okano M, Ueda T, Nishitani Y, Kano H, Ikekita A, Kageyama S.

Drug Test Anal. 2013 Mar;5(3):166-81. doi: 10.1002/dta.1394. Epub 2012 Aug 9.


A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.

Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, English DR, Hopper JL, Tilley WD, Mackenzie PI.

Mol Pharmacol. 2010 Oct;78(4):714-22. doi: 10.1124/mol.110.065953. Epub 2010 Jul 13.

Supplemental Content

Support Center